Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recovery After Sugammadex: TIVA vs Inhalation Anesthesia
NCT01579851Phase 4Completed
- Sponsor
- Hôpital Foch
- Start
- Jan 2012
- Primary completion
- Jan 2015
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Hôpital Foch. Primary endpoints: Number of patients with an increase in Bispectral Index after sugammadex injection at 1 hour and Number of patients with occurence of clinical signs of awakening after sugammadex injection at 1 hour. Started Jan 2012; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01579851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01579851.